Global Dry Eye Syndrome Market to Exhibit a CAGR of 4.7% and Hit USD 6.54 Billion by 2027; Growing Awareness about Eye Disorders to Incite Business Development, states Fortune Business Insights™

Pune, India, Jan. 07, 2021 (GLOBE NEWSWIRE) — The global dry eye syndrome market size is expected to reach USD 6.54 billion by 2027, exhibiting a CAGR of 4.7% during the forecast period. The increasing prevalence of chronic eye disorders and diseases will spur demand for eye treatment, which, in turn, will aid the expansion of the market. The global market size was USD 5.22 billion in 2019.The coronavirus incident has affected many industries and businesses around the world. The governments of several countries have instigated lockdown to thwart the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies to receive in-depth information about the present scenario of every market so that you can adopt the necessary strategies accordingly.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/dry-eye-syndrome-market-102413
Rising Awareness About Dry Eye Treatment to Incite DevelopmentThe increasing incidence of dry eye syndrome owing to the surging geriatric population will bolster the healthy growth of the market. The most common dry eye is associated with the chronic ophthalmic disorder, which has a high prevalence rate in old individuals compared to adults. The prevalence can be as high as 75.0% for individuals over the age of 40.The growing R&D investments by pharmaceutical companies in new therapeutics can have a tremendous impact on the global market. Moreover, the product launches with high efficacies due to increasing awareness and incidence can further improve the prospects of the market. The growing demand for better treatment outcomes and quality of life for patients can push the growth of the market.Weakened Dry Eye Drug Sales to Dampen Market Growth Amid COVID-19The market players experienced a strong decline in dry eye drug sales. For instance, Novartis AG witnessed a decline of -31.4% in the revenue of its dry eye product Xiidra. The drug generated a revenue of US$ 104.0 Mn in a quarter second of 2019 whereas it generated US$ 79 Mn in the second quarter of 2020. The significant decline in the number of new eye examinations has further hindered the sales of such products. Moreover, lockdown in several countries has restricted the transportation and distribution of dry eye drugs, which, in turn, restrict the growth of the market amid coronavirus
To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/dry-eye-syndrome-market-102413
Increasing Eye Treatment Procedure to Aid Expansion in North AmericaNorth America is expected to hold the largest share in the global dry eye syndrome treatment market during the forecast period. The presence of key manufacturers in the U.S. coupled with high awareness and incidence of dry eye syndrome in the U.S. and Canada are factors estimated to boost the expansion of the dry market in North America.Europe is expected to expand radically during the forecast period owing to the growing prevalence of dry eye in the European countries. Asia Pacific is expected to increase rapidly during the forecast period owing to growing awareness regarding eye disorders. The growing accessibility and adoption of high-cost treatment options will stimulate the healthy growth of the market in the forthcoming years.
Key Development:February 2019: ReGenTree announced the Phase – III clinical trial (ARISE-3 Study) of the new pipeline drug candidate called RGN-259 as a dry eye treatment for dry eye syndrome.
Quick Buy –  Dry Eye Syndrome Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102413
The Report Lists the Key Companies in this Market:ALLERGAN (Dublin, Ireland)Alcon (Geneva, Switzerland) Novartis AG (Basel, Switzerland)Santen Pharmaceutical Co., Ltd. (Japan)OASIS Medical (California, U.S.)Sun Pharmaceutical Industries Ltd (Mumbai, India)Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan)Sentiss Pharma Pvt. Ltd. (Haryana, India)Johnson & Johnson Vision Care, Inc. (Jacksonville, U.S.)VISUfarma (Amsterdam, Netherlands)Other Prominent Players
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/dry-eye-syndrome-market-102413
Table of Contents:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence Of Dry Eye Disease For Key CountriesKey Industry DevelopmentsPipeline AnalysisNew Product LaunchesReimbursement PoliciesRegulatory ScenarioOverview Of Novel Approaches To Treat Dry EyesKey Industry TrendsHealthcare Industry OverviewImpact of COVID-19 on the Global Dry Eye Disease Treatment MarketOverview of Over the Counter Eye Lubricants in the MarketGlobal Dry Eye Syndrome Market Analysis, Insights and Forecast, 2016-2027Key Findings / SummaryMarket Analysis, Insights and Forecast – By Product TypeAnti-inflammatoryCyclosporinLifitegrastCorticosteroidsOthersArtificial Tears and LubricantsMarket Analysis, Insights and Forecast – By Distribution ChannelsHospital PharmaciesRetail PharmaciesOnline PharmaciesOthersMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia PacificLatin AmericaMiddle East & Africa